Podcasts about Mount Sinai

One of the deadliest poisons known to man is now used to treat wrinkles, migraines, and even, maybe, depression. How did that happen? Guests: Jean Carruthers, ophthalmologist and “godmother” of cosmetic Botox. David Simpson, neurologist at Mount Sinai hospital in New York. Axel Wollmer, psychiatrist at the Asklepios clinic in Hamburg, Germany. For more, go to http://vox.com/unexplainable It's a great place to sign up for our newsletter, view show transcripts, and read more about the topics on our show. Also, email us! unexplainable@vox.com We read every email. Support Unexplainable by making a financial contribution to Vox! bit.ly/givepodcasts Learn more about your ad choices. Visit podcastchoices.com/adchoices Learn more about your ad choices. Visit podcastchoices.com/adchoices

In the phrase in Kaddish "Yitbarach Ve'yishtabah Ve'yitpa'ar…" the word "Ve'yishtabah" begins a series of seven words that consist of six letters each, for a total of 42 letters. This phrase thus alludes to the special "Shem Mem-Bet" – the 42-letter Name of G-d, which has special significance. If we add the other three words of praise in Kaddish – "Yitgadal," "Ve'yitkadash," and "Yitbarach," we arrive at a total of ten expressions of praise, which parallel the ten utterances with which Hashem created the universe. These ten pronouncements later found expression in the declaration of the Ten Commandments at Mount Sinai. The people heard the first two commandments from G-d, whereas the other eight were told only to Moshe who then conveyed them to the people. Accordingly, the ten expressions of praise in Kaddish are separated into two series: the two expressions of "Yitgadal" and "Ve'yitkadash" at the beginning of Kaddish, and the eight expressions from "Yitbarach" through "Ve'yit'halal," which appear later. The Peri Hadash (Rav Hizkiya Da Silva, 1659-1698) writes that these ten expressions of praise correspond to the ten different terms that King David used in Tehillim when praising Hashem (e.g. Nisu'ah, Niggun, Shir, Mizmor).

Ryan Mauro, a prominent international security analyst seen frequently on FOX News Channel and other media outlets, is one of only a handful of researchers to successfully visit Mount Sinai and the other Moses-related sites in Saudi Arabia before the country began allowing tourism.Become a supporter of this podcast: https://www.spreaker.com/podcast/the-opperman-report--1198501/support.

In this powerful and science-forward episode of the Tick Boot Camp Podcast, host Matt Sabatello sits down with Amy Proal, PhD, a leading microbiologist whose work is reshaping how the medical community understands chronic Lyme disease, post-treatment Lyme disease (PTLD), ME/CFS, and Long COVID. Dr. Proal brings a rare combination of deep scientific expertise, lived experience with chronic illness, and real-world clinical integration, offering listeners clarity on why so many patients remain sick long after standard treatment ends — and what science is finally doing about it.

By Ken Loucks - Following the Arc of the story of God's plan to dwell with mankind, this message explores how the book of Exodus moves that story forward. God brings the descendants of Abraham out of slavery in Egypt, brings them to Mount Sinai, and teaches them how to live as His people. He then has them build the

I greet you in Jesus' precious name! It is Friday morning, the 13th of March, 2026, and this is your friend, Angus Buchan, with a thought for today. We start in the Book of Exodus 34:2: “So be ready in the morning, and come up in the morning to Mount Sinai, and present yourself to Me there on the top of the mountain.” That is the Lord speaking to Moses early in the morning. Then we go to the Gospel of Mark 1:35: ”Now in the morning, having risen a long while before daylight, He went out and departed to a solitary place; and there He prayed.” That was Jesus Himself, early in the morning, the best time of the day. I have told you this many, many times. We need to start the day early in the morning with the Lord. Joseph Parker was a great preacher. He lived a long time ago and this is what he wrote:Sweet morning, there is hope in it's music,Blessed is the day whose morning is sanctified (set aside), Successful is the day whose first victory was won in prayer,Holy is the day whose dawn finds you on top of the mountain.(Listen to this) Health is established in the morning,Wealth is won in the morning,The light is brightest in the morning.We will stop there. I want to say to you today, it is time to start getting up a little bit earlier in the morning. Now, when Martin Luther, the great reformer was really, really busy, they said to him, “What do you do when your day is so busy? How do you handle it? Do you know what he said? He said, “I get up earlier in the morning.” So in other words, he didn't make his quiet time shorter because of the busy schedule for the day. No, he kept his quiet time the same length. He just got up earlier.I really want to encourage you to do that because that is what I have been doing for many, many years. The Lord speaks to me clearly early in the morning before the things of the world clutter up my mind. I get specific direction from Him, comfort from Him, health from Him. Set this time aside. Let your family know, let your children know, let your wife know, “I am spending time with God”, and they will not only respect you for that but they will also feel secure. Dad is praying, he is spending time with the Lord. Mom is praying, she is spending time with the Lord. Do you know what that does for children? It gives them security. Now, if you want to hear from God, get up in the morning. Maybe you need to go to bed a little bit earlier at night. Jesus bless you and have a beautiful quiet time this morning.Goodbye.

Dr. John Dickens talks with Dr. Eric Legome about innovations in trauma care to improve patient outcomes, how the ED role might evolve to address broader public health issues, mentorship's influence on career development, and more. 

God entered into covenant with the nation of Israel at Mount Sinai in 1440 BC, soon after God rescued Israel from slavery in Egypt. In this Covenant, God promised Israel bountiful blessings of success, prosperity, biological fertility, security and peace in the rich land of Canaan, and the #1 ranking among all the nations on earth, on one big condition; if Israel would faithfully obey the terms of the Covenant. If however, Israel would not obey the covenant terms, God would to send horrific curses of punishment upon His chosen people. The important question now, that we answer in this episode, is: How will Israel respond to their Covenant with God? Scripture referenced: Genesis 12:1-7, Exodus 19:1-8, Exodus 20:1-21, Exodus 24:1-18, Exodus 32:1-14, Exodus 33:1-3, Exodus 34:12-17, Leviticus 20:22-26, Leviticus 26:1-46, Numbers 14:1-11, Numbers 21:4-5, Numbers 25:1-3, Deuteronomy 12:30-31, Deuteronomy 28:1-68, Joshua 1:1-9, Joshua 3:1-17, Judges 2:6-15, Judges 3:7, Judges 21:25, 1 Samuel 8:1-8, 1 Samuel 9:15-16, 1 Samuel 10:1-2, 1 Samuel 16:1-13, 1 Samuel 17:1-54, 2 Samuel 5:1-10, 2 Samuel 6:1-4, 12-15, 2 Samuel 11:1-27, 1 Kings - 2 Kings, 1 Kings 11:4-8, 1 Kings 18:17-40, 1 Kings 19:9-10, 18, 2 Chronicles 33:1-10, Psalm 2:12, Psalm 16:11, Psalm 23:1-6, Isaiah 1:2-5, Isaiah 5:20, Isaiah 8:11-19, Jeremiah 2:4-32, Jeremiah 3:1-11, Jeremiah 4:22, Jeremiah 5:1-31, Jeremiah 7:8-26, Jeremiah 10:12-16, Jeremiah 11:1-10, Ezekiel 36:16-23, Malachi 1:1-14, Malachi 2:11, Romans 1:16-17, Ephesians 6:10-20, Colossians 1:9-14, Revelation 20:10-15

What is the kavod, the “glory” of God, so often referred to in the Bible? It settled on Mount Sinai and Moses begged to see it. All the earth is filled with it and Jeremiah teaches us to render glory to God. But what is it? In this episode we will answer not only these questions but a more pressing one: where is God's glory today? Sources: Ex. 24:16, 33:18, 40:, Isaiah 6:3, Jer. 13:16, Ps. 29:9,11, Guide 1:19, 54, 64, Kedusha of Mussaf for Shabbat.

Just like any family trip to a far away place, everyone starts getting grumpy quick. New questions arise about who may partake of the Passover and who should abstain. After Israel leaves Mount Sinai for the Promised Land they becomes dissatisfied with what the Lord provides, complaining that the food they had in Egypt was better than manna from the Lord. Moses complains to the Lord that these people aren't his babies and he shouldn't have to nurse them. Miriam and Aaron get jealous of the authority given to Moses, and criticize him in order to elevate themselves. Finally, their journey could have been over in almost no time, but instead of confronting their enemies as the Lord had commanded, they cower, complain, and make excuses. Numbers 9 – 1:16 .  Numbers 10 – 5:13 .  Numbers 11 – 10:57 .  Numbers 12 – 18:15 .  Numbers 13 – 21:07 .  Psalm 32 – 25:55 . :::Christian Standard Bible translation.All music written and produced by John Burgess Ross.Co-produced by Bobby Brown, Katelyn Pridgen, Eric Williamson & the Christian Standard Biblefacebook.com/commuterbibleinstagram.com/commuter_bibletwitter.com/CommuterPodpatreon.com/commuterbibleadmin@commuterbible.org

Exodus 19-20   These chapters are pivotal in book of Exodus. Israel arrives at Mount Sinai, where God meets with them and enters into a covenant with them. Because of that, these chapters are also pivotal in the history of Israel and the entire Bible.  God describes their status and vocation in Exodus 19:3-6:  3 And Moses went up to God, and the Lord called to him from the mountain, saying, “This is what you shall say to the house of Jacob and tell the sons of Israel: 4 ‘You yourselves have seen what I did to the Egyptians, and how I carried you on eagles' wings, and brought you to Myself. 5 Now then, if you will indeed obey My voice and keep My covenant, then you shall be My own possession among all the peoples, for all the earth is Mine; 6 and you shall be to Me a kingdom of priests and a holy nation.' These are the words that you shall speak to the sons of Israel.” God also gives Israel the 10 Commandments in Exodus 20 as the foundation of his covenant with them.    BIBLE READING GUIDE - FREE EBOOK - Get the free eBook, Bible in Life, to help you learn how to read and apply the Bible well: https://www.listenerscommentary.com     GIVE -  The Listener's Commentary is a listener supported Bible teaching ministry made possible by the generosity of people like you. Thank you! Give here:  https://www.listenerscommentary.com/give     STUDY HUB - Want more than the audio? Join the study hub to access articles, maps, charts, pictures, and links to other resources to help you study the Bible for yourself. https://www.listenerscommentary.com/members-sign-up   MORE TEACHING - For more resources and Bible teaching from John visit https://www.johnwhittaker.net

Today I have an awesome guest, Dr. Marc Lener, a psychiatrist who I've collaborated with on cases in the past. We have a rollicking conversation covering everything from misdiagnosing bipolar as depression to marijuana and who shouldn't use it to how AI is impacting the future of psychiatry. Highly recommend if you're interested in Black Mirror :) Dr. Lener studied the biological basis of behavior at the University of Pennsylvania, trained in clinical research and psychiatry at Mount Sinai, and continued his clinical research training at the National Institute of Mental Health focused on the brain science of depression. He is Founder of Singula Institute (https://www.singulainstitute.org/), and Founder and CEO of Singula Health, a health technology company developing AI-powered tools to make mental health diagnosis and treatment more precise and personalized.My newest venture, including ALL BRAND NEW POSTS EVERY DAY: https://buymeacoffee.com/drpsychmom/posts⁠https://buymeacoffee.com/drpsychmom/posts⁠Join my awesome Midlife Women's Group here: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠drpsychmom.com/mwg⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠To get over 200 more episodes, most recently "When Pets Make Your Relationship WORSE," subscribe here! ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://creators.spotify.com/pod/show/drpsychmomshow/subscribe⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ For my secret Facebook group, the "best money I've ever spent" according to numerous members: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.facebook.com/groups/drpsychmom⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠For coaching from DPM, visit ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.drpsychmom.com/coaching/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠For therapy or coaching, contact us at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.bestlifebehavioralhealth.com/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠

Surah Taha is the 20th chapter of the Qur'an. It is a Makkan surah consisting of 135 verses and focuses on strengthening faith, patience, and trust in Allah. A major part of the surah tells the story of Prophet Musa, including his encounter with Allah at Mount Sinai, his mission to guide Pharaoh, and the struggles of guiding the Children of Israel. The surah highlights Allah's mercy, the importance of prayer, and the reminder that guidance comes from remembering and following Allah's message. Overall, Surah Taha encourages believers to remain steadfast in faith, trust Allah during difficulties, and reflect on the consequences of rejecting divine guidance. This video series is a curated collection of reflections and summaries drawn from the 30 Days with the Qur'an series, where each Juz was explored over the month of Ramadan. While not a full tafsir, these concise and heartfelt talks aim to highlight key themes and insights from each Surah to inspire a deeper connection with the Qur'an. In this series, we've taken those reflections and focused them surah by surah, offering a dedicated video for each chapter of the Qur'an. The goal is to spark curiosity, build motivation, and encourage further study of the Qur'an in a manageable, engaging format. Whether you're revisiting familiar Surahs or exploring new ones, these summaries are here to help you pause, reflect, and fall in love with the Qur'an all over again.

Thanks for listening and if you enjoy this message please share with a friend and let us know by giving us a rating. You can find more information about New Hope at newhopechurch.tv and follow us on Instagram @newhopechurchtv If you need prayer or have made a decision today please visit newhopechurch.tv/prayer You can also watch our sermons at youtube.com/NHChurch

This is the eighth lesson in Dr. Lane G. Tipton's Reformed Academy course, The Theology of Heaven in the Book of Hebrews. This lesson covers the following topics: 00:00 The Contrast Between Two Mountains 02:05 Reading of Exodus 24 05:08 Mount Sinai's Three-Fold Partitioning Reflected in the Tabernacle 10:00 Moses' Ascent Up the Mountain Register for this free on-demand course on our website to track your progress and assess your understanding through quizzes for each lesson. You will also receive free access to dozens of additional video courses in covenant theology, apologetics, biblical studies, church history, and more: https://reformedacademy.org/course/th... Your donations help us to provide free Reformed resources for students like you worldwide: https://reformedforum.org/donate/ #heaven #hebrews #reformedtheology #biblestudy

Did you know that fertility rates have dropped 50% in the last 5 decades, and more and more people are requiring help to grow their family? Some are calling it "Spermageddon." I'm not one to run with fantastical headlines, but the truth is that we are facing an infertility epidemic. And, this is all heartbreaking for the people dealing with infertility, and for us as a society.   Today, I'm honored to be joined by Dr. Shanna Swan on The Egg Whisperer Show to talk about this upsetting truth. Dr. Swan is one of the world's leading environmental and reproductive epidemiologists and a Professor of environmental medicine and public health at the Icahn School of Medicine at Mount Sinai in New York City. An award-winning scientist, her work examines the impact of environmental exposures including chemicals such as phthalates and Bisphenol A, on men's and women's reproductive health and the neurodevelopment of children. She just recently published her book, "Countdown: How Our Modern World Is Threatening Sperm Counts, Altering Male and Female Reproductive Development, and Imperiling the Future of the Human Race."   We will be talking about the data and information that Dr. Swan has gathered, the environmental factors that are playing a role, and what we can do to reverse some of the impact. I hope you'll tune in and share this information far and wide. CountMeIn on changing this epidemic - and thank you for writing your eye-opening new book, Dr. Swan.   Read the full show notes on Dr. Aimee's website Subscribe to my YouTube channel for more fertility tips! Join Egg Whisperer School Checkout the podcast Subscribe to the newsletter to get updates Dr. Aimee Eyvazzadeh is one of America's most well known fertility doctors. Her success rate at baby-making is what gives future parents hope when all hope is lost. She pioneered the TUSHY Method and BALLS Method to decrease your time to pregnancy. Learn more about the TUSHY Method and find a wealth of fertility resources at www.draimee.org.

God didn't climb Mount Sinai to make life harder; He went there to move in. When He gave the Ten Commandments amid thunder, lightning, and smoke, it wasn't a power play. It was a covenant. The first four commandments shape how we relate to God; the next six shape how we treat each other. And when Israel responded with one voice, "Everything the Lord has said, we will do," it was a moment of total surrender to a God who simply wanted to live among His people. But that raises a question worth sitting with today: Are there rooms in your life with the door still locked? God's commands aren't guardrails meant to cage you — they're the care of a Father protecting what matters most.Pursuing God with Gene Appel is designed to help you pursue God, build community, and unleash compassion. Grounded in Scripture and shaped by Eastside's conviction that God's grace is for everyone, each episode invites you to discover God's presence and activity in your life.

Daniel goes on a solo podcast adventure to:- Talk about the whooping NYCFC gave Orlando- The upcoming game against Colorado- The interview with Brad Simms- It wasnt Montefoire hospital, it was Mount Sinai, Im an idiot, lol.

Jesus Christ in 3 Nephi 21 spoke of two signs. This episode discusses the first sign given about America's Independence. We will uncover the hidden mystery and connect the dots of how the Declaration of Independence is tied to the Moses and the Golden Calf incident at Mount Sinai.

After delivering His people from slavery, parting the Red Sea, and providing daily bread in the wilderness, God gathered Israel at Mount Sinai and gave them the Ten Commandments, not as a burden, but as a blessing. These commands weren't meant to restrict freedom but to protect it, like guardrails on a dangerous road. They reveal what life looks like when love for God and love for others shape every choice. The law was never a ladder to earn God's approval; it's a mirror that shows our need for grace and a guide that helps us flourish. So the real question is, how do we see God's commandments? As control… or as care from a Father who wants to protect what matters most?Pursuing God with Gene Appel is designed to help you pursue God, build community, and unleash compassion. Grounded in Scripture and shaped by Eastside's conviction that God's grace is for everyone, each episode invites you to discover God's presence and activity in your life.

Are the Ten Commandments still relevant today, or does modern society think it can update them? In this episode of Mark & Pete, we explore why the Ten Commandments, biblical morality, and Christian ethics still shape Western civilisation and why many people now believe they should be rewritten for the modern age.Across politics, culture, and social media, there is growing talk of rewriting moral rules to fit modern values. Some commentators suggest humanity needs a new set of commandments – updated for climate change, technology, and social trends. But can the Ten Commandments from the Bible really be replaced, or are they more foundational than we realise?In this conversation we examine the history of the Ten Commandments in Christianity, their influence on law and culture, and the deeper reason they still provoke debate thousands of years after Moses received them on Mount Sinai. From “You shall not murder” to “You shall not steal,” these commandments have shaped moral thinking in the West for centuries.The episode also looks at a modern question: if society believes it can improve on biblical law, what replaces it? Are moral rules now decided by governments, cultural trends, or popular opinion?Along the way we discuss Christian theology, biblical authority, moral law, and the role of faith in public life, asking whether modern society is abandoning ancient wisdom too quickly. The Ten Commandments were never meant to be merely historical artefacts. They were intended as a guide for human life before God.Whether you are interested in Christian apologetics, theology, culture, ethics, or the influence of the Bible on Western society, this episode explores why the Ten Commandments continue to provoke debate in the modern world.Subscribe for thoughtful discussions on faith, culture, politics, and biblical wisdom delivered with clear reasoning and a touch of dry British humour.Keywords:Ten Commandments relevance today, updating the Ten Commandments, Christian morality modern society, biblical ethics debate, Ten Commandments Christianity, Bible moral law, Mount Sinai commandments, Christian apologetics culture, Mark and Pete podcast, faith and culture commentary

In this powerful episode of the Double Edged Sword podcast, Father Genard shares essential Christian Lent fasting tips rooted in Scripture and Assyrian Church of the East canons, defining fasting as true abstinence (soma in Aramaic) from food and drink—exemplified by Jesus' 40-day fast, Adam's prohibition from the tree of knowledge, and Moses on Mount Sinai. He outlines three practical methods for offering your fast during Lent's required weeks (first, middle, and last): full-day abstinence until Vespers (sundown) with constant prayer and Scripture; abstinence until lunchtime, then soma-compliant meals (no dairy, poultry, or seafood, though honey is allowed); or full-day soma food without strict abstinence for those unable. Father Genard stresses that Lent fasting transcends food scrutiny—focus instead on examining sins like hatred, pride, gossip, immorality, and lust, while avoiding temptation triggers (especially porn and inappropriate social media) as desires intensify (James 1:14). Supported by church tradition (2 Thessalonians 2:15) and extreme calls to holiness (Matthew 18:8-9), he urges blocking evil influences, distancing from sinful relationships, countering Satan's lies with Scripture (Hebrews 12:2, Ezekiel 33:11), and combining faith with good works like prayer and fasting for spiritual victory and eternal life.Bible Verses Mentioned (Orthodox Study Bible / Common Orthodox Translation Phrasing):Genesis 2:17 — but of the tree of the knowledge of good and evil you shall not eat, for in the day that you eat of it you shall surely die.Matthew 4:1-2 — Then Jesus was led up by the Spirit into the wilderness to be tempted by the devil. And when He had fasted forty days and forty nights, afterward He was hungry.2 Thessalonians 2:15 — Therefore, brethren, stand fast and hold the traditions which you were taught, whether by word or our epistle.James 1:14 — But each one is tempted when he is drawn away by his own desires and enticed.Matthew 18:8-9 — If your hand or foot causes you to sin, cut it off and cast it from you. It is better for you to enter into life lame or maimed, rather than having two hands or two feet, to be cast into the everlasting fire. And if your eye causes you to sin, pluck it out and cast it from you. It is better for you to enter into life with one eye, rather than having two eyes, to be cast into hell fire.Hebrews 12:2 — looking unto Jesus, the author and finisher of our faith, who for the joy that was set before Him endured the cross, despising the shame, and has sat down at the right hand of the throne of God.Ezekiel 33:11 — Say to them: ‘As I live,' says the Lord GOD, ‘I have no pleasure in the death of the wicked, but that the wicked turn from his way and live. Turn, turn from your evil ways! For why should you die, O house of Israel?'Psalm 37:1-2 — Do not fret because of evildoers, nor be envious of the workers of iniquity. For they shall soon be cut down like the grass, and wither as the green herb.2 Timothy 3:16-17 — All Scripture is given by inspiration of God, and is profitable for doctrine, for reproof, for correction, for instruction in righteousness, that the man of God may be complete, thoroughly equipped for every good work.1 Timothy 3:15 — but if I am delayed, I write so that you may know how you ought to conduct yourself in the house of God, which is the church of the living God, the pillar and ground of the truth.Romans 6:21 — What fruit did you have then in the things of which you are now ashamed? For the end of those things is death.2 Peter 3:10 — But the day of the Lord will come as a thief in the night, in which the heavens will pass away with a great noise, and the elements will melt with fervent heat; both the earth and the works that are in it will be burned up.Titus 2 (referenced generally for speaking things that are proper/sound doctrine and avoiding shameful things so no one despises you).

Exodus 15:22-18:27   These chapters of Exodus recount Israel's journey from the Red Sea to Mount Sinai. It includes five snapshots from that journey which show Israel's continual unbelief that's acted out in grumbling and complaining and pining to return to Egypt.  The five snapshots are: 1. Near dehydration - 15:22-27 2. Fear of Starvation - 16:1-36 3. No more water - 17:1-7 4. Fighting Amalek - 17:8-16 5. A Father-in-Law's Advice - 18:1-27     BIBLE READING GUIDE - FREE EBOOK - Get the free eBook, Bible in Life, to help you learn how to read and apply the Bible well: https://www.listenerscommentary.com     GIVE -  The Listener's Commentary is a listener supported Bible teaching ministry made possible by the generosity of people like you. Thank you! Give here:  https://www.listenerscommentary.com/give     STUDY HUB - Want more than the audio? Join the study hub to access articles, maps, charts, pictures, and links to other resources to help you study the Bible for yourself. https://www.listenerscommentary.com/members-sign-up   MORE TEACHING - For more resources and Bible teaching from John visit https://www.johnwhittaker.net

In this message from Exodus 19, we explore one of the most important moments in Israel's story—when God meets His people at Mount Sinai and clearly defines what a relationship with Him looks like. Before giving commands, God reminds Israel of His grace: He rescued them from slavery, carried them through the wilderness, and brought them to Himself. Then He invites them into a covenant relationship where they will be His treasured possession, a kingdom of priests, and a holy nation. Just as every meaningful relationship eventually asks the question, "What are we?", God also calls us to define our relationship with Him. Through Jesus, the new covenant makes that relationship clearer than ever. The question we're left with is simple but profound: God has defined His relationship toward us—how will we define our relationship with Him?

What happens when the people of Israel miscalculate Moses' return from Mount Sinai — and panic sets in? In this week's Torah portion, Ki Tisa, we explore one of the most dramatic and painful episodes in the entire Torah: the fashioning of the Golden Calf.As Moses spends 40 days and 40 nights atop Har Sinai, communing with God and receiving the Torah, the people grow restless. They lose track of time, grow anxious, and begin to fear the worst — "What has happened to Moses?" In their uncertainty, they turn to Aaron with a desperate request: give us something tangible, a stand-in for the Divine presence that has guided us.What follows is a lesson about faith, fear, and what we reach for when our spiritual anchor seems to disappear.Rabbi Dweck has held rabbinic leadership roles in the US and the UK. He is the Rosh Bet Midrash of TheHabura.com and the Rabbi Levy Chair of Jewish Wisdom at the London School of Jewish Studies.For more, check out rabbijosephdweck.com.Instagram: https://instagram.com/rabbidweckTikTok: https://www.tiktok.com/@rabbidweckYoutube: https://www.youtube.com/c/RabbiJosephDweck Rabbi Dweck has held rabbinic leadership roles in the US and the UK. He is the Rosh Bet Midrash of TheHabura.com and the Rabbi Levy Chair of Jewish Wisdom at the London School of Jewish Studies.For more, check out rabbijosephdweck.com.Instagram: https://instagram.com/rabbidweckTikTok: https://www.tiktok.com/@rabbidweckYoutube: https://www.youtube.com/c/RabbiJosephDweck

Ana Fernández Sesma, Catedrática y directora del Departamento de Microbiología de la Facultad de Medicina Icahn en el Mount Sinai, en  Nueva York, y su colega Adolfo García Sastre, director del Global Health & Emerging Pathogens Institute en la misma Icahn School of Medicine at Mount Sinai, protagonizan Ágora. Ambos científicos, virólogos e inmunólogos de reputación mundial, participan en el Zaragoza en las Jornadas de Actualización en Gripe, un encuentro organizado por CSL Seqirus, uno de los mayores productores mundiales de vacunas de la gripe, la Asociación Española de Vacunología y la Asociación Nacional de Enfermería y Vacunas, entre otras. Ágora queda con ellos para conversar sobre virus, virus de la gripe sobre todo, patógenos, pandemias, vacunas y Salud Pública.

This National Kidney Month, we celebrate the unsung heroes of the human body. Kidneys do so much more than filter blood (they've been described as the body's “cleaning crew” and “inventory managers”), so keeping them functioning well is vital to our overall health. Joining us to sing the praises of kidneys – and learn how to keep them healthy – is Dr. Kristin Meliambro, an Associate Professor in the Department of Medicine, Division of Nephrology at the Icahn School of Medicine at Mount Sinai. Dr. Meliambro walks us through the many essential jobs kidneys do for us and breaks down the various causes of kidney disease. She also shares practical lifestyle habits that support long-term kidney health.   The Takeaway We want to hear from you! Please complete our survey: org/member-feedback. Drop us a line at our social media channels: Facebook// Instagram // YouTube. Find out where your health stands by making an appointment with your primary care physician. Don't have one? Find one at our Provider Directory: www.1199SEIUBenefits.org/find-a-provider. Visit the Healthy Living Resource Center for wellness tips, information and resources; 1199SEIUBenefits.org/healthyliving. Get to know your numbers at www.1199SEIUBenefits.org/healthyhearts. Need support managing chronic conditions such as type 2 diabetes, hypertension or overweight? Learn about our partnerships: visit www.1199SEIUBenefits.org/the-choice-is-yours/ Browse healthy recipes and meal-prep tips at 1199SEIUBenefits.org/food-as-medicine. For additional information and support, visit the National Kidney Foundation website, at Kidney.org, and the American Association of Kidney Patients, at www.aakp.org. For information about kidney donation, visit the Nation Kidney Registry page at KidneyRegistry.com Get inspired by fellow members through our Members' Voices series: 1199SEIUBenefits.org/healthyliving/membervoices. Stop by our Benefits Channel to join webinars on building healthy meals, managing stress and more: 1199SEIUBenefits.org/videos. Visit our YouTube channel to view a wide collection of healthy living videos: youtube.com/@1199SEIUBenefitFunds/playlists. Sample our wellness classes to exercise body and mind: 1199SEIUBenefits.org/wellnessevents.   Guest Bio Kristin Meliambro, MD, is an Associate Professor in the Department of Medicine, Division of Nephrology at the Icahn School of Medicine at Mount Sinai. She earned her medical degree from the Icahn School of Medicine at Mount Sinai, and she completed both her internal medicine residency and clinical and research nephrology fellowships at the Mount Sinai Hospital. In addition to treating patients with a wide range of kidney diseases in diverse clinical settings, Dr. Meliambro is an NIH-funded physician-investigator who conducts basic and translational research with a focus on mechanisms of kidney podocyte injury and novel disease therapies. She is the co-Director of the Nephrology Division's Renal Biorepository, which banks biological specimens and collects clinical data from patients starting at the time of kidney biopsy and continuing longitudinally. She also actively participates as a PI and Co-Investigator in clinical trials testing novel agents for glomerular diseases. Dr. Meliambro also has a strong record of research mentorship of Associate Researchers and graduate/medical students in her lab, the majority of whom have been women and from under-represented minorities in science and medicine. Dr. Meliambro sees patients with a variety of kidney diseases, and she has a particular clinical interest in glomerular diseases. Her clinical responsibilities include the care of outpatients at the Mount Sinai Doctors nephrology practice, hemodialysis patients at Central Park Dialysis Center and inpatients at the Mount Sinai Hospital, where she also teaches and supervises nephrology fellows on the inpatient nephrology services.

In the conclusion of our series, Familiar Stranger, Lead Pastor Jason Britt looks at the birth of the Church in Acts 2. We often entertain ourselves with the "supernatural" on a screen through movies and shows, yet we often struggle to embrace the supernatural reality of the Holy Spirit in our actual lives. If everything about our salvation is supernatural—from the Virgin Birth to the Resurrection—why would we expect to sustain our Christian walk through natural strength alone? Pastor Jason connects the dots between the giving of the Law at Mount Sinai and the pouring out of the Spirit at Pentecost. While the Law was once written on stone, the Holy Spirit now writes it on our hearts. Being a "Spirit-filled person" isn't about chasing miracles; it's about a life so marked by Jesus that it can only be explained by His power. When we move from "trying" to "trusting," we become the witnesses God called us to be.

We are beginning the book of Leviticus; which basically means, “pertaining to the Levites,” as this book dives deeper into the responsibilities of priests and the divine-human relationship codified on Mount Sinai. The Lord gives Moses instructions for offering different kinds of sacrifices to be made before the Lord, allowing an impure people to be made holy by obedience to a perfect God. We'll look at four kinds of offering today. The burnt offering is given with prayer or praise to seek God's face and favor. The grain offering is generally offered alongside another offering. The fellowship offering emphasizes fellowship with the Lord by having a communion meal. Finally, the sin offering is given to atone for sin that has been committed. Leviticus 1 - 1:00 .  Leviticus 2 - 3:50 .  Leviticus 3 - 7:36 .  Leviticus 4 - 10:23 .  Psalm 40 - 17:04 .  :::Christian Standard Bible translation.All music written and produced by John Burgess Ross.Co-produced by the Christian Standard Bible.facebook.com/commuterbibleinstagram.com/commuter_bibletwitter.com/CommuterPodpatreon.com/commuterbibleadmin@commuterbible.org

Hebrews: The True and Better - Hebrews 12:18-29Jobey McGintyWe all know the feeling of wanting to draw near to God but feeling unworthy or unsure. Hebrews 12 reminds us that our nearness to God isn't based on performance or perfection. We haven't come to Mount Sinai—a place of fear and distance—but to Jesus, and to grace. Through Christ, God invites us close, not because we are strong but because He is faithful. This passage calls us to lay down fear‑driven worship, receive an unshakable kingdom, and draw near with grateful, confident hearts.

Norman Parker:- This House Pt.5: The Big Story:- From Fulfillment To Completion https://drive.google.com/file/d/1Juo5hc440G79aU-AbKKtUb_F4YmkK4fh/view?usp=sharingKey Themes and Biblical References: Jesus our Apostle and High Priest: The message explores how Jesus is building His house. Hebrews 3:1 encourages believers to "fix your thoughts on Jesus, whom we acknowledge as our apostle and high priest". Questions for reflection include what it means for Jesus to be our apostle and high priest, and what it means to share in the "heavenly calling". Passover and Pentecost: John the Baptist identified Jesus as "the Lamb of God, who takes away the sin of the world". The one who sent John to baptize with water indicated that the one on whom the Spirit descends and remains will "baptise with the Holy Spirit". The Unique Relationship between Jesus and the Father (James Torrance): The center of the New Testament is the "unique relationship between Jesus and the Father". Through the Spirit, Christ presents Himself "on behalf of humankind" and draws people to participate "both in his life of worship and communion with the Father and in his mission". This relationship is interpreted through the Holy Spirit: Jesus is conceived, baptized, led, offers himself through the eternal Spirit on the cross, is raised by the Spirit, and receives the Spirit from the Father to baptize the church. Contrasting Mountains (Hebrews 12): The Mountain of Fear refers to the terrifying sight of Mount Sinai, with fire, darkness, and storm, where Moses trembled. The Mountain of Joy refers to Mount Zion, the heavenly Jerusalem, where believers have come to "thousands upon thousands of angels," "the church of the firstborn," and "Jesus the mediator of a new covenant". The Point of Pentecost (N.T. Wright): The overarching story of Scripture is not about humans going to live with God, but about "God's intention to come and live with us and even in us". Pentecost is the "homecoming of God," fulfilling the promise to "dwell in and with his People".

Exodus 20 // Jonathan NeefIn this teaching on Exodus 20, we look at the heart of the biblical law and the significance of the Ten Commandments. The sermon breaks down the two sections of the tablets: the first focusing on our devotion to God—prohibiting idols and honoring his name—and the second focusing on our conduct toward our neighbors. We discuss the awe-inspiring atmosphere of the mountain, the thunder and lightning that accompanied his voice, and the role of Moses as a mediator. This sermon invites us to see these commandments as a reflection of his holy character and a roadmap for a life of justice and peace.SERMON NOTES (YouVersion): https://bible.com/events/49569652 PRAYER REQUESTS: https://ccefc.ccbchurch.com/goto/forms/2542/responses/new26.03.01

As Israel stands at Mount Sinai, God does not begin with random rules — He begins with revelation. Before command comes covenant. Before requirement comes redemption. “I am the Lord your God who brought you out of Egypt.” Relationship comes before regulation.In this message, we explore the first three commandments and the foundational alignment they demand in every generation. These commandments are not merely restrictions; they establish the structure of a flourishing life and a faithful people.They answer three essential questions:What is ultimate? — God alone is the ultimate good. When anything else takes His place, life becomes disordered.Who is God? — He is transcendent and cannot be reduced, reshaped, or controlled. We do not remake Him in our image; He reshapes us in His.Who are we? — We are carriers of His name. To take His name in vain is not only careless speech, but careless representation. We bear His name in how we live.These commandments call us to right allegiance, right understanding, and right representation. They confront our idols, protect God's otherness, and remind us that our lives either honor or misrepresent the One we claim to follow.And ultimately, this alignment is not something we accomplish in our own strength. The Holy Spirit empowers us to make God ultimate, to yield to His transforming presence, and to carry His name faithfully in the world.Follow: The Story of the ExodusExodus 20:1–7

Exodus 20 // Brooks NesseIn this teaching on Exodus 20, we look at the heart of the biblical law and the significance of the Ten Commandments. The sermon breaks down the two sections of the tablets: the first focusing on our devotion to God—prohibiting idols and honoring his name—and the second focusing on our conduct toward our neighbors. We discuss the awe-inspiring atmosphere of the mountain, the thunder and lightning that accompanied his voice, and the role of Moses as a mediator. This sermon invites us to see these commandments as a reflection of his holy character and a roadmap for a life of justice and peace.SERMON NOTES (YouVersion): https://bible.com/events/49569653 PRAYER REQUESTS: https://ccefc.ccbchurch.com/goto/forms/2509/responses/new26.03.01

Exodus 20 // Rachel NesseIn this teaching on Exodus 20, we look at the heart of the biblical law and the significance of the Ten Commandments. The sermon breaks down the two sections of the tablets: the first focusing on our devotion to God—prohibiting idols and honoring his name—and the second focusing on our conduct toward our neighbors. We discuss the awe-inspiring atmosphere of the mountain, the thunder and lightning that accompanied his voice, and the role of Moses as a mediator. This sermon invites us to see these commandments as a reflection of his holy character and a roadmap for a life of justice and peace.SERMON NOTES (YouVersion): https://bible.com/events/49569654 PRAYER REQUESTS: https://ccefc.ccbchurch.com/goto/forms/2553/responses/new26.03.01

Exodus 20 // Taylor FairIn this teaching on Exodus 20, we look at the heart of the biblical law and the significance of the Ten Commandments. The sermon breaks down the two sections of the tablets: the first focusing on our devotion to God—prohibiting idols and honoring his name—and the second focusing on our conduct toward our neighbors. We discuss the awe-inspiring atmosphere of the mountain, the thunder and lightning that accompanied his voice, and the role of Moses as a mediator. This sermon invites us to see these commandments as a reflection of his holy character and a roadmap for a life of justice and peace.SERMON NOTES (YouVersion): https://bible.com/events/49569655 PRAYER REQUESTS: https://ccefc.ccbchurch.com/goto/forms/2546/responses/new26.03.01

There is frankly a LOT of discussion about the relationship of the "Law" to believers in Jesus Christ. To muddy the waters more, there is a question about which law we're talking about - the Mosaic law (given to Jews at Mount Sinai) which has both ritual and moral laws, the books of the law (Genesis to Deuteronomy), the law that is the whole of the OT, the law of Christ (coming in chapter 6!), or the royal law (James 2:8). Paul will help us understand the purpose and beauty of the law as we continue in chapter 3 this week.

Exodus 20 // Paul BrandesIn this teaching on Exodus 20, we look at the heart of the biblical law and the significance of the Ten Commandments. The sermon breaks down the two sections of the tablets: the first focusing on our devotion to God—prohibiting idols and honoring his name—and the second focusing on our conduct toward our neighbors. We discuss the awe-inspiring atmosphere of the mountain, the thunder and lightning that accompanied his voice, and the role of Moses as a mediator. This sermon invites us to see these commandments as a reflection of his holy character and a roadmap for a life of justice and peace.SERMON NOTES (YouVersion): https://bible.com/events/49569651PRAYER REQUESTS: https://ccefc.ccbchurch.com/goto/forms/2574/responses/new26.03.01

You Can't Retire From Purpose Dr. Alan Rozanski on the Six Domains of Health and What It Really Means to Age Well In this episode, I sit down with Dr. Alan Rozanski — cardiologist, lifestyle medicine physician, professor at the Icahn School of Medicine at Mount Sinai, and a founding pioneer of behavioral cardiology. With nearly 300 published articles, Dr. Rozanski has spent 40 years studying how our physical and mental behaviors shape heart health.What We CoverThe Aha Moment. Forty years ago, Dr. Rozanski watched patients' heart function deteriorate while simply talking about stress — just as it would on a treadmill. That observation launched a career exploring the mind-body connection.The Six Domains of Health.Physical Health — Exercise, resistance training, sleep, and nutrition. After 30, we lose 3–8% of muscle mass per decade. Resistance training can slow that decline.Mindset — Optimists live longer and show better biological markers. Gratitude costs nothing but attention.Emotional Well-Being — Chronic depression is one of the heart's greatest threats. Happiness builds resilience and extends life.Social Connection — The size and quality of your social network is a powerful predictor of longevity.Sense of Purpose — "You can retire from a job, but you can never retire your need for purpose."Stress Management — Mild challenge stress promotes growth. Toxic, uncontrollable stress damages health. Boredom carries its own quiet risks.The Biology. Mental states translate into physical disease through stress hormones, insulin resistance, inflammation, and even changes in brain structure. The good news: many of these changes are reversible.Mental Clutter. Scattered attention drains energy. Focused work sprints and intentional recovery help protect mental clarity.Healthcare Today. Dr. Rozanski speaks candidly about the geriatrician shortage, confusing nutritional guidelines, eroding doctor-patient time, and AI's emerging role in restoring it.Key Takeaway Health is not the absence of disease — it is vitality. That feeling is available at 19, 60, and 99. The six domains are six doorways. Wherever you are, one of them is a place to start.Connect with Dr. Rozanski Website: alanrozanski.com | LinkedIn: Dr. Alan RozanskiConnect with Dr. Alan Rozanski

Study Passage: Exodus 24:12,15-18, Exodus 25:1-9, & Exodus 31:1-1112 The LORD said to Moses, “Come up to me on the mountain and wait there, that I may give you the tablets of stone, with the law and the commandment, which I have written for their instruction.” 15 Then Moses went up on the mountain, and the cloud covered the mountain. 16 The glory of the LORD dwelt on Mount Sinai, and the cloud covered it six days. And on the seventh day he called to Moses out of the midst of the cloud. 17 Now the appearance of the glory of the LORD was like a devouring fire on the top of the mountain in the sight of the people of Israel. 18 Moses entered the cloud and went up on the mountain. And Moses was on the mountain forty days and forty nights.Exodus 25:1-91 The LORD said to Moses, 2 “Speak to the people of Israel, that they take for me a contribution. From every man whose heart moves him you shall receive the contribution for me. 3 And this is the contribution that you shall receive from them: gold, silver, and bronze, 4 blue and purple and scarlet yarns and fine twined linen, goats' hair, 5 tanned rams' skins, goatskins, acacia wood, 6 oil for the lamps, spices for the anointing oil andfor the fragrant incense, 7 onyx stones, and stones for setting, for the ephod and for the breastpiece. 8 And let them make me a sanctuary, that I may dwell in their midst. 9 Exactly as I show you concerning the pattern of the tabernacle, and of all its furniture, so you shall make it.Exodus 31:1-11The LORD said to Moses, 2 “See, I have called by name Bezalel the son of Uri, son of Hur, of the tribe of Judah, 3 and I have filled him with the Spirit of God, with ability and intelligence, with knowledge and all craftsmanship, 4 to devise artistic designs, to work in gold, silver, and bronze, 5 in cutting stones for setting, and in carving wood, to work in every craft. 6 And behold, I have appointed with him Oholiab, the son of Ahisamach, of the tribe of Dan. And I have given to all able men ability, that they may make all that I have commanded you: 7 the tent of meeting, and the ark of the testimony, and the mercy seat that is on it, and all the furnishings of the tent, 8 the table and its utensils, and the pure lampstand with all its utensils, and the altar of incense, 9 and the altar of burnt offering with all its utensils, and the basin and its stand, 10 and the finely worked garments, the holy garments for Aaron the priest and the garments of his sons, for their service as priests, 11 and the anointing oil and the fragrant incense for the Holy Place. According to all that I have commanded you, they shall do.”

In this powerful teaching from Isaiah 64, we unpack the rich Hebraic background behind phrases like “rend the heavens,” “come down,” and “the mountains might shake.” These are not random poetic expressions. They are layered idioms filled with covenantal, prophetic, and eschatological meaning. What does it mean to ask God to tear open the heavens? Why do mountains symbolize governments? How does this passage connect to Mount Sinai, the Exodus, and the future Tribulation? This study reveals: • The Hebraic meaning of “rend the heavens” • How “coming down” connects to Sinai and divine intervention • Why mountains represent kingdoms and authority structures • Israel's future national repentance in the Tribulation • The difference between spiritual salvation and physical deliverance • The biblical meaning of the Potter and the Clay • A contextual breakdown of Romans 9 in light of Jeremiah 18 • Why misunderstanding Hebraisms leads to theological confusion We also explore the personal application. When God delays intervention in our lives, what is He teaching us? How does remembering past deliverance build faith for future rescue? Understanding the Jewish background of Scripture brings clarity to passages that are often misunderstood, especially in debates surrounding sovereignty, free will, and replacement theology. If you want to understand the Old Testament foundations behind the New Testament, and how prophetic passages fit into God's redemptive plan for Israel and the nations, this teaching will deepen your perspective. Subscribe for weekly biblical teaching, prophecy updates, and in-depth studies from Rock Harbor Church.

In our last episode, Israel had turned away from the Lord while Moses was with the Lord on Mount Sinai. Even though they had just committed themselves to following the Lord God, they quickly lost their resolve and turned to Aaron, who in turn gave them a golden calf to worship. After this grave sin, God tells Moses He will no longer go with Israel to the land He had promised Abraham and his descendants after him. Today, Moses intercedes on their behalf, assuaging God's anger and garnering his favor. Later, God's appointed craftsmen are called out to begin assembling the tabernacle according to the Lord's instructions. Exodus 33 - 1:00 .  Exodus 34 - 6:39 .  Exodus 35 - 14:31 .  Psalm 36 - 19:55 .  :::Christian Standard Bible translation.All music written and produced by John Burgess Ross.Co-produced by the Christian Standard Bible.facebook.com/commuterbibleinstagram.com/commuter_bibletwitter.com/CommuterPodpatreon.com/commuterbibleadmin@commuterbible.org

Dr. Lakshmi Rajdev and Dr. Manish Shah join the podcast to discuss the updated guideline on immunotherapy and targeted therapy in unresectable locally advanced, advanced, or metastatic gastroesophageal cancer. They share first-line and subsequent-line recommendations for both gastroesophageal adenocarcinoma and esophageal squamous cell carcinoma based on actionable biomarkers including PD-L1 expression, MMR and/or MSI, CLDN18.2 expression, and HER2 status. They note the importance of the algorithms and tables in the guidelines that provide visual illustrations and quick reference guides of the evidence-based recommendations. They also comment on ongoing and recently presented trials that may impact future guidelines in this space. Read the full guideline, "Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline Update" at www.asco.org/gastrointestinal-cancer-guidelines" TRANSCRIPT This guideline, clinical tools and resources are available at www.asco.org/gastrointestinal-cancer-guidelines. Read the full text of the guideline and review authors' disclosures of potential conflicts of interest in the Journal of Clinical Oncology,  https://ascopubs.org/doi/10.1200/JCO-25-02958      Timestamps ·       00:00 – 02:15 Introduction and Overview ·       02:16 - 08:20 First-line treatment for patients with pMMR/MSS, HER2-negative gastroesophageal adenocarcinoma ·       08:21 –10:29 First-line treatment for patients with pMMR/MSS, HER2-positive gastroesophageal adenocarcinoma ·       10:30 – 14:39 First-line treatment for patients with dMMR/MSI-H, gastroesophageal adenocarcinoma ·       14:40 – 18:03 First-line treatment for ESCC ·       18:04 – 22:04 Second- and third-line therapy for gastroesophageal adenocarcinoma and ESCC ·       22:05 – 24:38 Importance of guideline ·       24:39 – 27:45 Outstanding questions and future research   Brittany Harvey: Hello and welcome to the ASCO Guidelines podcast, one of ASCO's podcasts delivering timely information to keep you up to date on the latest changes, challenges, and advances in oncology. You can find all the shows, including this one, at asco.org/podcasts.   My name is Brittany Harvey, and today I am interviewing Dr. Lakshmi Rajdev from the Icahn School of Medicine at Mount Sinai and Dr. Manish Shah from Weill Cornell Medicine, co-chairs on "Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline Update." Thank you for being here today, Dr. Rajdev and Dr. Shah. Dr. Lakshmi Rajdev: Thank you. Dr. Manish Shah: Thank you for having us. It is wonderful. Brittany Harvey: And then just before we discuss this guideline, I would like to note that ASCO takes great care in the development of its guidelines and ensuring that the ASCO conflict of interest policy is followed for each guideline. The disclosures of potential conflicts of interest for the guideline panel, including Dr. Rajdev and Dr. Shah, who have joined us here today, are available online with the publication of the guideline in the Journal of Clinical Oncology, which is linked in the show notes. So then to dive into what we are here today to talk about, Dr. Shah, I would like to start first with what prompted the update to this guideline, which was previously published in 2023, and what is the scope of this updated guideline? Dr. Manish Shah: Yes, terrific. So even in the last few years, the pace of drug development in gastroesophageal cancers has just been astounding. So, what prompted this guideline is actually the practice-changing results for a new biomarker, CLDN18.2 hat was based on the GLOW and SPOTLIGHT studies, as well as a practice-changing study in HER2-positive disease where we added pembrolizumab to trastuzumab and chemotherapy for tumors that are HER2-positive and PD-L1 CPS 1 or greater. And then there were also new studies and new approvals in esophageal squamous cell cancer that you will hear about as well. So there were several studies, overall more than 5,000 patients were reported on, and that led to several new therapies, new indications, and it really necessitated this guideline. Brittany Harvey: Excellent. It is great to hear about all of these exciting updates in this space. So then to next review the key recommendations of this guideline by clinical question that the expert panel addressed. So, Dr. Rajdev, what is the recommended first-line treatment for patients with proficient mismatch repair, microsatellite stable, HER2-negative gastroesophageal adenocarcinoma? Dr. Lakshmi Rajdev: Thank you for that question. So historically, we have sort of used fluoropyrimidine and platinum doublets, which yielded a survival of about one year. More recently, immunotherapy and targeted therapy options have improved outcomes in patients with advanced esophageal and gastric adenocarcinoma, as well as squamous cell carcinoma. Patients with gastric and GE junction adenocarcinoma have a high rate of actionable alterations, so it is imperative that physicians test the following biomarkers upfront so that it can help guide therapy. The markers recommended by the ASCO panel are HER2, MMR or MSI, CLDN18.2, and PD-L1. And also, it was recommended to use NGS if feasible in this patient population. HER2, as we know, is expressed in about 15% to 25% of patients; PD-L1 expression occurs in about 80% of patients; MSI-high, deficient MMR is present in about 5% to 8% of patients; and CLDN18.2 expression is present in about 40% of patients. There is, of course, biomarker overlap. About 13% to 22% of CLDN18.2 patients are also PD-L1 positive. For patients with pMMR or microsatellite stable HER2-negative disease with PD-L1 expression greater than 1 and absence of CLDN18.2, the panel recommended a first-line therapy with fluoropyrimidine and platinum-based therapy in combination with immunotherapy. These recommendations stem from large phase 3 trials, and the agents approved in the United States are pembrolizumab, nivolumab, and tislelizumab. It has been shown that immunotherapy benefit is greater in patients with higher PD-L1 expression, and it is not possible to comment on the individual PD-L1 cutoff scores and sort of identify the optimal PD-L1 cutoff score that sort of balances benefits and harms. But what is recommended is that immunotherapy-based treatments can be offered in patients with a CPS score of greater than 1. With regard to the choice of immunotherapy agents, that is pembrolizumab, nivolumab, or tislelizumab, these agents are considered to have similar efficacy, and the selection of an agent could be based on dosing schedule, cost considerations, toxicity, and the method of administration. Typically, clinicians should avoid withholding the start of chemotherapy while awaiting biomarker testing, depending on the clinical scenario. Now, for patients with pMMR microsatellite stable disease that is HER2-negative with PD-L1 expression less than 1 and positive CLDN18.2 expression, zolbetuximab-based treatments or in combination with chemotherapy is recommended, and this is based on two global phase III randomized controlled trials, the GLOW and the SPOTLIGHT. And across both studies, the hazard ratio for the overall survival was 0.78, and similarly, there was also an improvement in progression-free survival favoring the zolbetuximab group compared to the chemotherapy group alone. An important note is that nausea, vomiting is commonly associated with zolbetuximab-based treatments, and the panel recommended prophylactic antiemetics, adjusting zolbetuximab infusion rates, pausing infusion temporarily, using non-prophylactic antiemetics, and hydration intravenously prior to discontinuation of zolbetuximab-based chemotherapy. So effective handling of the GI-related symptoms with zolbetuximab is recommended prior to discontinuation of therapy. Now, for patients with pMMR microsatellite stable HER2-negative gastric, GE junction adenocarcinoma with PD-L1 expression greater than 1 and CLDN18.2 positivity, the ones with the dual expression with CLDN18.2 as well as PD-L1 chemotherapy, the choice of therapy can be based on the degree of PD-L1 expression, the toxicity profile, the burden of symptoms, and the anticipated improvement in symptoms associated with response to treatment, the patient comorbidities, the prior medical and treatment history. So this decision needs to be made on a case-by-case basis, and these are some of the factors that we suggested that could potentially influence the choice of therapy. For patients with pMMR microsatellite stable disease that is HER2-negative and a PD-L1 expression less than 1 and an absence of CLDN18.2 expression, first-line therapy with fluoropyrimidine and platinum-based chemotherapy is recommended. So you can see we have segmented out patients based on PD-L1 expression, pMMR and microsatellite stable disease expression, and also based on CLDN expression. Brittany Harvey: Absolutely. And that first point you noted, I think is really important, that biomarker testing is really critical for treatment decision-making in this space. So then the next subgroup of patients that the panel looked at, Dr. Shah, what first-line therapy is recommended for patients with proficient mismatch repair, microsatellite stable, HER2-positive gastroesophageal adenocarcinoma? Dr. Manish Shah: So this was an update from a few years ago. So we have known for 15 years now that if you are HER2-positive, you should get trastuzumab plus chemotherapy. That was based on the ToGA trial. And the update now is based on a trial called KEYNOTE-811, where it examined the addition of pembrolizumab to trastuzumab and chemotherapy versus trastuzumab and chemotherapy, and there was a progression-free and overall survival benefit. And again, here, the biomarkers are important. If your CPS PD-L1 is less than 1, we would not recommend Pembrolizumab in that setting, so you would still get trastuzumab and chemotherapy. But if it is 1 or greater, the PD-L1 CPS score, then we do recommend pembrolizumab unless there is a contraindication to immunotherapy. The take-home message really is from the onset of diagnosis, please check your biomarkers. And I will just, it is worth repeating, it is important to check your PD-L1 status, HER2 status, mismatch repair status, and CLDN18.2 status. And then the optimal therapy, and it is outlined in the publication, is really biomarker-driven. We know that if we are able to hit the target that is overexpressed, we are going to have a better outcome. And Dr. Rajdev did mention where there is overlap, there can be a lack of data, and that is where we are with both PD-L1 positive and CLDN positive. Here we do have data in HER2-positive cases where if you are both HER2-positive and PD-L1 positive, you would combine trastuzumab and pembrolizumab for the best outcomes. Brittany Harvey: Understood. I really appreciate you detailing what is most important for each individual biomarker combination that patients may have. So then following that, Dr. Rajdev, what does the expert panel recommend for first-line treatment for patients with esophageal squamous cell carcinoma that is not amenable to definitive chemoradiation? Dr. Lakshmi Rajdev: There are three phase III randomized clinical trials that have influenced practice in patients with esophageal squamous cell carcinoma examining the benefit of immunotherapy in this patient population. The RATIONALE-306 was a randomized trial of tislelizumab plus chemotherapy with platinum and fluoropyrimidine or paclitaxel versus placebo with chemotherapy. And then you have the KEYNOTE-590, which compared pembrolizumab plus chemotherapy versus chemotherapy alone. And then you have CheckMate-648, which included comparisons of nivolumab plus chemotherapy versus nivolumab plus ipilimumab or chemotherapy. And the primary endpoints for these studies were overall survival, and they did look at subgroups with PD-L1 expression. They used TPS score greater than 1% in CheckMate-648 and PD-L1 CPS greater than 10 in KEYNOTE-590. The bottom line is that the overall hazard ratio for overall survival across this patient population was 0.72. So clearly, there is benefit in patients that express PD-L1 CPS greater than 1 for benefit for the addition of immunotherapy. Now, the benefit again in patients with a PD-L1 expression less than 1 remains limited, and so the panel has made a recommendation for using immunotherapy in combination with platinum-based chemotherapy in patients with a PD-L1 greater than 1. Again, we know that it is hard to make recommendations on what PD-L1 cutoffs are recommended in this patient population, meaning that should it be limited to patients with a PD-L1 of 1 to 4 or greater than 10? I think that the general consensus that has been gleaned from the data is that the higher the PD-L1 expression, the greater the benefit. I do want to comment on another option that is available in patients with squamous cell carcinoma compared to adenocarcinoma, and that is the combination of nivolumab and ipilimumab. Now, in CheckMate-648, nivolumab with ipilimumab was also recommended as a treatment option in patients that have a PD-L1 score of greater than 1. There was a survival benefit demonstrated with this combination compared to chemotherapy alone. And an important observation in this study is that, although there was a slightly increased rate in early death, but there was really no significant difference in PFS and OS compared to chemotherapy alone. Importantly, the treatment appeared to be pretty well tolerated by the study population. There was a notable difference in the objective response rate, which was 35% in the nivolumab plus ipilimumab group compared to patients receiving nivolumab and chemotherapy, where it was 53%. So superiority is, so the importance of chemotherapy in patients with esophageal squamous cell carcinoma is to be noted. However, there is no difference in overall survival and progression-free survival when using the combination of nivolumab and ipilimumab, and thus it affords a chemotherapy-free option for this patient population with esophageal squamous cell carcinoma and a CPS with a score of greater than 1. Brittany Harvey: Understood. I appreciate you reviewing the evidence underpinning those recommendations as well. So then the next patient population that the guideline panel addressed, what first-line therapy is recommended for patients with deficient mismatch repair, microsatellite instability-high, gastroesophageal adenocarcinoma or esophageal squamous cell carcinoma? Dr. Lakshmi Rajdev: The rate of MSI-high expression is about 3% to 7% across different studies. Now, the KEYNOTE-158 was a tumor-agnostic study in patients with non-colorectal cancers, and again, the problem with the MSI-high population, given that it is so rare, the numbers in the individual studies are fairly small. But consistent outcomes do emerge, indicating high response to immunotherapy. So in KEYNOTE-158, a response rate of about 46% was noted. The number of patients was small, it was about 24. In CheckMate-649, which is a study of chemotherapy plus or minus nivolumab in patients with advanced gastric adenocarcinoma, there was again a very small number of patients, and patients that were MSI-high or deficient MMR did experience substantial benefits with the addition of immunotherapy, with hazard ratios in the order of about 0.38. In KEYNOTE-062, again, it was a very small number of patients, again about 6% or so, and similar to CheckMate-649, a substantial benefit was noted in combination with chemotherapy, but also there were benefits noted with pembrolizumab alone. The RATIONALE-305 again was a study of tislelizumab in combination with chemotherapy and similarly showed benefits to the combination of chemotherapy plus immunotherapy in this patient population. I think that we are all aware of the dramatic benefits of immunotherapy in this particular subset of patients, deficient MMR MSI-high, and also we have seen in CheckMate-649 they did have a subset of patients that received nivolumab and ipilimumab. And in this patient population, they noted unstratified hazard ratio of 0.28. So I think that the overall consensus is that immunotherapy is a very important treatment modality in patients with deficient MMR MSI-high disease, given that a lot of the trials in gastroesophageal adenocarcinoma have utilized chemotherapy-based options, that is certainly a recommendation of the panel to use chemotherapy in combination with immunotherapy. However, on a case-by-case basis, the panel recommended immunotherapy alone as well, and given the high response rates noted in trials across different diseases as well as noted in this disease as well. Brittany Harvey: Certainly. And I appreciate you both for reviewing these first-line recommendations. So moving to later lines of therapy, Dr. Rajdev, what recommendations did the expert panel make for second or third-line therapy for gastroesophageal adenocarcinoma and esophageal squamous cell carcinoma? Dr. Lakshmi Rajdev: So, I think that the RAINBOW trial that investigated the utility of the addition of ramucirumab as second-line therapy has been around since 2014, and those results have led to the addition of ramucirumab to taxane-based therapy in the second-line setting. Based on the utilization of oxaliplatin and platinum-based therapy in the front-line setting, there may be patients that have an underlying neuropathy, and so we wanted to really include treatment options for this patient population so that an agent that is less neurotoxic could also be recommended in combination with ramucirumab. The RAMIRIS trial is one such trial where ramucirumab was combined with FOLFIRI, and it demonstrated benefit in combination with ramucirumab. So we have listed that as a potential treatment option for patients in the second-line setting who may have an underlying neuropathy or even for whatever reason that based on the toxicity profile, that needs to be the preferred option by a physician, that recommendation is new from the older guidelines that we have. With regard to the utility of PD-1 inhibitors, there really has been no benefit noted in the second-line setting with regard to overall survival or progression-free survival, so no recommendation is made for that option. I think an important study that has been recently presented is the DESTINY-Gastric04 trial, which really has been practice-changing and has led to the recommendation for trastuzumab deruxtecan in patients that have HER2-positive metastatic gastric or GE junction adenocarcinoma. Now, this is a phase III trial in patients who retained HER2-positive disease after progressing on front-line trastuzumab-based treatments, and the comparator for this trial was trastuzumab deruxtecan versus ramucirumab plus paclitaxel. There was significant improvement and progression-free survival in patients that received trastuzumab deruxtecan. The patients that were excluded from the trial are patients that have pulmonary problems, interstitial lung disease; that is one of the toxicities of this particular agent, and close monitoring and prompt initiation of therapy such as glucocorticoid treatment in patients who develop this toxicity was also highlighted by the panel. So to summarize, the new guidelines highlight the possibility of FOLFIRI plus ramucirumab as a second-line option and then trastuzumab deruxtecan as a later-line option in patients that still retain HER2 expression. And that is very important because the trial did retest patients whether they expressed HER2. As we know, in a substantial number of patients, there is downregulation of HER2, and there is emerging data that the benefit for subsequent HER2-directed therapies is best noted in patients that still retain HER2 expression. Brittany Harvey: Great. So as our listeners have heard, there are many recommendations and new treatment options for advanced gastroesophageal cancer. Dr. Shah, earlier you highlighted the importance of biomarker testing, but I would like to hear in your view, what is the importance of this guideline and how will it impact both clinicians and patients with gastroesophageal carcinoma? Dr. Manish Shah: So as we have discussed throughout this podcast, the treatment for gastroesophageal cancer, both adenocarcinoma and squamous cell cancer, is increasingly complex, increasingly biomarker-driven. And I think the value of the guideline is to place all of that into context. So it provides the data for why certain biomarkers are important, what therapies should be indicated. Not only that, but if you are able to review the guideline, it provides the details of each of these studies and summarizes them in a meta-analysis fashion to sort of give you the context, because sometimes the individual studies can be maybe a little bit discordant or confusing and the guideline attempts to harmonize all that. And then also, I think the tables are very, very interesting because they give you actual numbers in terms of how many patients over a thousand would this benefit or how many patients over a thousand would this cause harm in terms of nausea, vomiting, or other things like that. So it gives you context for helping clinicians and patients weigh the potential benefits of the novel treatment strategies against the potential adverse events. And then finally, the guideline does also provide an algorithm that you are able to follow based on the biomarkers, and those are in figures 4 and 5. So I think overall, it is a very comprehensive guideline. It intends to make more manageable a very complex subject, and you know, I really encourage our listeners to review it after listening to the podcast. Dr. Lakshmi Rajdev: If I can add to that, I think that what is also really good about the guidelines is there are quick summaries. So if someone is busy in the clinic, of course, there is the opportunity to review the data supporting the guidelines in great depth in the manuscript, but what is also really good is that there are good summaries. In the event that you are very busy, you can easily identify what the recommendations should be for that particular patient based on these summaries. Brittany Harvey: Absolutely. Listeners are encouraged to review the full guideline, including those tables and figures that may be more helpful when they are looking for something quick to look at in the clinic as well. So, as you both mentioned, there have been a number of recent practice-changing trials in this area. So I imagine there is still a lot of ongoing research as well. So Dr. Shah, what are the outstanding questions regarding treatment options for patients with locally advanced unresectable, advanced, or metastatic gastroesophageal carcinoma? Dr. Manish Shah: I think we touched upon it a little bit. The guidelines are based on the data available, and they are primarily examining one novel therapy with chemotherapy in a specific biomarker population. But as you know, the biomarkers are not either/or; you are not either CLDN18.2 positive or PD-L1 positive. A portion of patients could have dual biomarkers, and you know, I think that we are generating data on how to manage those patients. At the recent GI Symposium in January this year, the ILUSTRO trial was presented by Dr. Shitara, which looked at combining zolbetuximab and chemotherapy with immunotherapy for dual-positive biomarkers, and that is leading to a phase III study that has begun to enroll. So unanswered questions are: how do we manage dual-positive biomarkers? The other thing that was mentioned is that the current data for mismatch repair deficiency involve chemotherapy plus immunotherapy. Only squamous cell cancer is there a study with a positive non-chemotherapy kind of backbone, that is CheckMate-648 that Dr. Rajdev mentioned. As we move forward, it will be good to get data on non-chemotherapy options in certain biomarker-positive populations. And then finally, another update, which is likely to be practice-changing, is the HERIZON-GEA-01 study that looked at zanidatamab, which is another biparatopic antibody that targets HER2, and that is likely to change practice. And as that data gets published, we may look to even do a rapid update for the current immunotherapy and targeted therapy guideline that is just being published. Dr. Lakshmi Rajdev: So, if I can add to that, there are numerous ADCs that look very interesting. There are bispecific antibodies; in fact, the zanidatamab is a bispecific antibody showing improved activity in patients with HER2-positive disease. So I think there are studies from Asia looking at CLDN CAR T-based therapies. So, I think that there are a lot of novel agents and a lot of excitement in the field. We know that the bemarituzumab study, unfortunately, the FGFR2 inhibitor failed to demonstrate any benefit, but I think that there are other agents that are being explored, so there are newer targets, newer agents, ADCs, bispecifics that could potentially change the field in the future. Brittany Harvey: Yes, we will look forward to the data to address these unanswered questions and new agents and inform future guideline updates. So, I would like to thank you both for all of your work to review the evidence here and update this important guideline, and for your time today, Dr. Rajdev and Dr. Shah. Dr. Lakshmi Rajdev: Thank you. Dr. Manish Shah: Thank you. Brittany Harvey: And finally, thank you to all of our listeners for tuning in to the ASCO Guidelines podcast. To read the full guideline, go to www.asco.org/gastrointestinal-cancer-guidelines. You can also find many of our guidelines and interactive resources in the free ASCO Guidelines app, which is available in the Apple App Store or the Google Play Store. If you have enjoyed what you have heard today, please rate and review the podcast and be sure to subscribe so you never miss an episode. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.

In this powerful teaching from Isaiah 64, we unpack the rich Hebraic background behind phrases like "rend the heavens," "come down," and "the mountains might shake." These are not random poetic expressions. They are layered idioms filled with covenantal, prophetic, and eschatological meaning. What does it mean to ask God to tear open the heavens? Why do mountains symbolize governments? How does this passage connect to Mount Sinai, the Exodus, and the future Tribulation? This study reveals: • The Hebraic meaning of "rend the heavens" • How "coming down" connects to Sinai and divine intervention • Why mountains represent kingdoms and authority structures • Israel's future national repentance in the Tribulation • The difference between spiritual salvation and physical deliverance • The biblical meaning of the Potter and the Clay • A contextual breakdown of Romans 9 in light of Jeremiah 18 • Why misunderstanding Hebraisms leads to theological confusion We also explore the personal application. When God delays intervention in our lives, what is He teaching us? How does remembering past deliverance build faith for future rescue? Understanding the Jewish background of Scripture brings clarity to passages that are often misunderstood, especially in debates surrounding sovereignty, free will, and replacement theology. If you want to understand the Old Testament foundations behind the New Testament, and how prophetic passages fit into God's redemptive plan for Israel and the nations, this teaching will deepen your perspective. Subscribe for weekly biblical teaching, prophecy updates, and in-depth studies from Rock Harbor Church.

Biologics have changed how patients with asthma are able to handle their symptoms and prevent them from getting worse. Host Amy Attaway, MD, Cleveland Clinic, talks with Monica Kraft, MD, Icahn School of Medicine at Mount Sinai, and De De Gardner, DrPh, Allergy and Asthma Network and member of PAR about depemokimab, the newest biologic for those with severe asthma. Learn how this novel treatment is used once every six months to improve patient outcomes, as well as the research behind this biologic and the future of asthma treatment. Read Dr. Kraft's paper on depemokimab: https://journal.chestnet.org/article/S0012-3692(25)00855-4/pdf  Editor's note: During this episode, Dr. Kraft mistakenly said that depemokimab was approved for treating nasal polyps. Please note that depemokimab is not approved for treating this condition. 

We are beginning the book of Leviticus; the title basically means, “pertaining to the Levites,” as this book dives deeper into the responsibilities of priests and the divine-human relationship codified on Mount Sinai. These are instructions on how an impure people can be made holy by obedience to a perfect God. We'll look at four kinds of offering today. The burnt offering is given with prayer or praise to seek God's face and favor. The grain offering is generally offered along with another offering. The fellowship offering emphasizes fellowship with the Lord by having a communion meal. Finally, the sin offering is given to atone for sin that has been committed. Leviticus 1 – 1:15 .  Leviticus 2 – 3:57 .  Leviticus 3 – 7:34 .  Leviticus 4 – 10:09 .  Leviticus 5 – 17:32 .  Proverbs 16:1-16 :::Christian Standard Bible translation.All music written and produced by John Burgess Ross.Co-produced by Bobby Brown, Katelyn Pridgen, Eric Williamson & the Christian Standard Biblefacebook.com/commuterbibleinstagram.com/commuter_bibletwitter.com/CommuterPodpatreon.com/commuterbibleadmin@commuterbible.org

In this episode, Pastor Peter challenges us to commit to the practice of drawing near to the Lord, reminding us that we are either moving closer to God or drifting away. He emphasizes that true intimacy requires more than just lip service (Isaiah 29:13); it demands a true heart that seeks the living God as a deer pants for water (Psalm 42:1). By examining the Israelites' encounter with God at Mount Sinai in Exodus 19, Pastor Peter contrasts the "wrong kind of fear" that keeps people at a distance with the fear of the Lord that empowers us to enter the deep darkness where God dwells. Because of the single, perfect sacrifice of Jesus, we now have confidence to enter holy places and are commissioned as a kingdom of priests to minister in His presence (Hebrews 10:19, 22). Ultimately, we are urged to set our hearts on pilgrimage (Psalm 84:5), abandoning "dumb rocks" of safety to embrace a generational revival and a gospel of power that prepares the way for the Lord.

Bamidbar 10 is a momentous chapter. After a year at Mount Sinai, the nation embark to realize Jewish history, the promises to the Patriarchs, the fulfillment of the Exodus - they begin the march to Eretz Yisrael!

In this episode, Debra Jaeger, SVP and Chief Revenue Officer at Mount Sinai, shares how she is unifying fragmented revenue operations, improving cash collections and denials, and leveraging AI, predictive analytics, and workforce development to modernize the revenue cycle and enhance the patient financial experience.

New York City nurses are returning to work at some hospitals, while the strike drags on at NewYork-Presbyterian. Nancy Hagans, president of the New York State Nurses Association, talks about the latest and responds to criticism from rank-and-file members who say top union brass circumvented their negotiating committee to force a vote on a previously rejected proposal.